Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Retained Earnings (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Retained Earnings for 3 consecutive years, with $143000.0 as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Retained Earnings fell 83.66% year-over-year to $143000.0, compared with a TTM value of $143000.0 through Sep 2021, down 83.66%, and an annual FY2020 reading of -$118.2 million, down 131.95% over the prior year.
  • Retained Earnings was $143000.0 for Q3 2021 at Black Diamond Therapeutics, up from -$182.9 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $1.0 million in Q2 2020 and bottomed at -$182.9 million in Q2 2021.
  • Average Retained Earnings over 3 years is -$51.6 million, with a median of -$25.4 million recorded in 2019.
  • Peak annual rise in Retained Earnings hit 100.53% in 2021, while the deepest fall reached 18170.75% in 2021.
  • Year by year, Retained Earnings stood at -$51.0 million in 2019, then plummeted by 131.95% to -$118.2 million in 2020, then skyrocketed by 100.12% to $143000.0 in 2021.
  • Business Quant data shows Retained Earnings for BDTX at $143000.0 in Q3 2021, -$182.9 million in Q2 2021, and $335000.0 in Q1 2021.